Overview

 

Pacific GeneTech is a leading developer of next-generation vaccines which target areas of high unmet need in livestock animal health and food safety using Aegis, our proprietary development platform.

PGT_Milestone Chart
Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and livestock animal health. The global animal vaccine market is a valuable opportunity and is expected to reach US$20.6 billion by 2021. Livestock illness can lead to human infections, poor feed conversion, or loss of animals, making it a significant economic burden to producers.

Founded in 2009, Pacific GeneTech focuses on developing and commercializing vaccines for the livestock industry through our proprietary Aegis platform  which have broad cross-protection. In 2012, we acquired the exclusive global rights to Hercules Adjuvant Delivery System to enhance Aegis developed vaccines and explore partnership opportunities for other vaccine products. Since our founding, we have sought to expand Aegis vaccines into high-burden diseases across livestock species. Our lead vaccine targeting Salmonella and Campylobacter in poultry is expected to launch in 2019.

Poultry is an enormous growth driver in global meat production, in response to expanding global demand for more affordable animal protein. Human Salmonellosis (Salmonella poisoning) is the most common foodborne bacterial disease in the world and is often linked back to poultry products.

We develop and commercialize next-generation vaccines and also identify high value discovery-stage opportunities that will be first in class and/or best in class assets via research collaborations with world-leading institutions around the world. Pacific GeneTech also partners with global and regional animal health and livestock companies for the Hercules adjuvant and Aegis platform to generate commercial revenue on these partnered products. Our first product to market was a Hercules adjuvated vaccine . We continue to identify licensing opportunities for our vaccines and adjuvants.